Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

LIGNOSPAN FORTE

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

Standard Dose
EQ 0.02MG BASE/ML;2%
Max Dose
Refer to approved labeling
Primary Use
Review priority: UNKNOWN Marketing status: Prescription
Summary

Approval overview LIGNOSPAN FORTE is listed in Drugs@FDA under application 088389 (ANDA).

Review priority: UNKNOWN Marketing status: Prescription Active ingredient EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2% Sponsor DEPROCO Submission history Latest submission status date: 2025-06-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview LIGNOSPAN FORTE is listed in Drugs@FDA under application 088389 (ANDA). Review priority: UNKNOWN Marketing status: Prescription Active ingredient EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 0.02MG BASE/ML;2% Sponsor DEPROCO Submission history Latest submission status date: 2025-06-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: UNKNOWN

Interaction Notes

  • No interaction notes stored yet.